Ruxolitinib is Under Investigation as a JAK Inhibition Strategy for Multiple Myeloma
The observed clinical benefit of ruxolitinib concomitant with methylprednisolone and lenalidomide in relapsed/refractory multiple myeloma was an overall response rate (ORR) of 31% for the initial 2‑drug combination and 30% once lenalidomide was added; median progression‑free survival (PFS) remained 3.5 months regardless of additional therapy.
These data support evaluation of JAK inhibition as a therapeutic avenue in refractory myeloma, a disease with limited options after standard salvage regimens.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management